The rate of HIV infection continues to climb globally. Around 40 million people live with HIV-1, the most common HIV strain. While symptoms can now be better managed with lifelong treatment, there is ...

A new antiretroviral target has been identified that suppresses HIV-1 replication and selectively kills HIV-1-infected cells. HIV-1 is the most common type of HIV. When HIV-1 leaves infected cells, ...

Researchers at Johns Hopkins Medicine, in collaboration with researchers at the National Institutes of Health, report that two new studies in mice with a humanized immune system and human cell lines ...

Since HIV’s discovery in the 1980s, scientists have come a long way in understanding the different steps required for its assembly and maturation. Researchers knew, for instance, that HIV wraps its ...

University of Delaware professor Juan Perilla (right), is co-author of a new paper that reveals a previously unknown structural role for integrase, a key HIV protein, earlier in the virus' life cycle ...

Excision BioTherapeutics has so far released positive safety data from the first 3 participants living with HIV-1, with no evidence of vector shedding in sexual organ tissue. A cure for HIV-1 becomes ...

Though Gilead Sciences made waves last June with a landmark FDA approval for its twice-yearly HIV preventive Yeztugo (lenacapavir), the first-in-class drug had previously been used as a long-acting ...